These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23987046)

  • 41. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
    Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Optimum initial dose of silodosin for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia].
    Wada N; Numata A; Yamaguchi S; Osanai H; Mori T; Hou K; Fujisawa M; Kaneko S; Kakizaki H
    Hinyokika Kiyo; 2011 Jun; 57(6):297-302. PubMed ID: 21795831
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The use of desmopressin as an alternative in the treatment of nycturia in patients with benign prostatic hyperplasia (BPH)].
    Granados Loarca EA; Garat Barredo JM; Villavicencio Mavrich H
    Actas Urol Esp; 1999 Jan; 23(1):56-9. PubMed ID: 10089634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alfuzosin: a clinically uroselective alpha1-blocker.
    Höfner K; Jonas U
    World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.
    Sun GH; Tsui KH; Wu TT; Chang CH; Cheng CL; Schou M
    Kaohsiung J Med Sci; 2010 Oct; 26(10):532-9. PubMed ID: 20950778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia.
    Shahar E; Nassar L; Kedem E; Hassoun G
    Curr Drug Saf; 2014; 9(2):159-60. PubMed ID: 24861992
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Experience of the use of drug urorec: efficacy and safety].
    Kadiev RM; Derevianko TI
    Urologiia; 2014; (3):44, 46-7. PubMed ID: 25211926
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia.
    Güner S; Mutlu B; Güner E; Taşçi AI
    Arch Ital Urol Androl; 2010 Dec; 82(4):195-7. PubMed ID: 21341561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial].
    Pushkar' DIu; Loran OB; Petrov SB; Kogan MI; Zhuravlev VN
    Urologiia; 2008; (1):23, 25-6. PubMed ID: 18649675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Editorial comment from Dr Funahashi to α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
    Funahashi Y
    Int J Urol; 2013 May; 20(5):521. PubMed ID: 23131001
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.